Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

ZS Pharma

This page shows the latest ZS Pharma news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

AZ acquired Lokelma ( sodium zirconium cyclosilicate) via a $2.7bn acquisition of ZS Pharma three years ago, but suffered serious setbacks in its approval thanks to manufacturing compliance issues.

Latest news

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... AZ acquired Lokelma via the $2.7bn acquisition of ZS Pharma three years ago

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... The European approval finally puts AZ on course to make a return from its $2.7bn purchase of Lokelma’s originator ZS

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    AZ and ZS Pharma are committed to working with the FDA to resolve the remaining matters under review as soon as possible," it said in a statement. ... When AZ bought ZS Pharma it described ZS-9 as a "best in class" potassium-binder with sales potential

  • AZ nears EU approval for hyperkalaemia drug Lokelma AZ nears EU approval for hyperkalaemia drug Lokelma

    The drug was originally developed by ZS Pharma, which described Lokelma as a “potential best-in-class treatment” and tipped it as a potential blockbuster. ... Speaking at the time of ZS Pharma's acquisition, AstraZeneca's chief executive Pascal

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The CRL refers to a manufacturing issue. ZS-9 was acquired when the company purchased ZS Pharma for $2.7bn. ... Reported in DW Issue 65 [November 2015] AstraZeneca had out bid Actelion who were also in the running to buy ZS Pharma at that time.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    metabolism. Meanwhile, further evidence for an uptick in pharma industry interest in HF is witnessed by recent licensing/acquisition deals. ... of ZS Pharma and ZS-9, a drug being developed to treat elevated potassium levels in HF patients.

  • Deal Watch November 2015 Deal Watch November 2015

    Also doing the double and buying and selling AstraZeneca continued its busy deal profile with the acquisition of ZS Pharma and the divestment in the US of Entocort. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9, potassium-binding

  • Pharma deals in September 2015 Pharma deals in September 2015

    Transformational deals. The two largest deals announced this month were Cinven's sale of Amdipharm Mercury (AMCo) to Concordia Healthcare and Actelion's move to acquire ZS Pharma, at $3.5bn ... 3, 500. ZS Pharma. Actelion. ZS-9 to treat hyperkalemia

  • Sales reps struggle to access doctors Sales reps struggle to access doctors

    Relationships reached by sales force size. Source: ZS Associates. Making proper use of that well-worn buzz word 'customer-centric' marketing will be key - along with careful channel choice – if pharma ... companies are to gain physician attention, but

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....

Quick links